LifeCycle Pharma A/S, Minutes Extraordinary General Meeting


Company Announcement no. 08/2008
To: OMX Nordic Exchange Copenhagen		            Hørsholm, Denmark, March 14,
2008 

 
LifeCycle Pharma A/S, Extraordinary General Meeting March 14, 2008 regarding
change of authorisation for the Board of Directors to increase the Share
Capital and 
Consideration and Approval of General Guidelines for Incentive Pay to the
Members of the Board of Directors and Executive Management 

Summary: On the general meeting the authorisation to the board of directors to
increase the share capital  was changed from nom. DKK 10,000,000 to nom. DKK
25,000,000 and General Guidelines for Incentive Pay to the Members of the Board
of Directors and Executive Management were approved. 

On 14 March 2008 an Extraordinary General Meeting was held in LifeCycle Pharma
A/S, CVR-no. 26527767, at the address Radisson SAS Scandinavia Hotel, Amager
Boulevard 70, 2300 Copenhagen S. 

The general meeting approved the proposal to change article 9 in the articles
of association to the effect that the authorisation for the board of directors
to increase the share capital was increased from nominal DKK 10,000,000 to
nominal DKK 25,000,000. 

Hereafter article 9 will be worded as follows: 

“Article 9

The Board of Directors is in the period up until 1 July 2011 authorised, at one
or more times, to increase the Company's share capital with up to nominal DKK
25,000,000. 

Capital increases according to this authorisation can be carried out by the
Board of Directors by way of contributions in kind (including e.g. take over of
existing businesses), conversion of debt and/or cash capital contributions and
can be carried out with or without pre-emptive subscription rights for the
Company's shareholders at the discretion of the Board of Directors. 

The new shares shall be negotiable shares issued to bearer, but may be recorded
on name. The new shares shall not have any restrictions as to their
transferability and no shareholder shall be obliged to have the shares redeemed
fully or partly. The shares shall be with the same rights as the existing share
capital on the date of the capital increase. The new shares shall give rights
to dividends and other rights in the Company from the time which is determined
by the Board of Directors in connection with the decision to increase the share
capital.” 

The general meeting approved the board's proposal for general guidelines for
incentive pay to the members of the board of directors and executive
management. 

A new article 19 to the Company's article of association was inserted with the
following wording: 

”Guidelines for incentive pay
§ 19

”On the general meeting held on March 14, 2008, the Company adopted general
guidelines for incentive pay to the members of the board of directors and
executive management.” 

Without undue delay after approval by the general meeting, the guidelines will
also be made public on the Company's website (www.lcpharma.com) where it will
also be stated that the guidelines were adopted on the general meeting held on
March 14, 2008. 

There were no further points for discussion. 

About LifeCycle Pharma A/S (“LCP”)

LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the U.S. market and a
diversified near- and medium-term pipeline, including five product candidates
in clinical trials and three in preclinical stages of development. LCP is
listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX:
LCP). For further information, please visit www.lcpharma.com. 

******


For further information please contact LifeCycle Pharma A/S: 
Flemming Ornskov, MD
President and CEO  
+45 2420 0368; FO@lcpharma.com 
or:
Hans Christian Teisen 
Senior Vice President  & CFO
+45 20 30 69 85;  E-mail: hct@lcpharma.com

Attachments

140308 lifecycle pharma held extraordinary general meeting.pdf